Last reviewed · How we verify
Tislelizumab Injection
Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells.
Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic esophageal squamous cell carcinoma, Locally advanced or metastatic urothelial carcinoma.
At a glance
| Generic name | Tislelizumab Injection |
|---|---|
| Also known as | Tislelizumab, BGB-A317, BeiGene, Dacarbazine |
| Sponsor | Nanjing Leads Biolabs Co.,Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, tislelizumab prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on the surface of cancer cells. This blockade restores the immune system's ability to recognize and attack cancer cells, leading to anti-tumor activity.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic esophageal squamous cell carcinoma
- Locally advanced or metastatic urothelial carcinoma
- Adenocarcinoma of the stomach
- Gastric cancer
- Esophageal cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Cough
- Pyrexia
- Decreased appetite
- Vomiting
- Headache
Key clinical trials
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (PHASE2, PHASE3)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (PHASE2)
- A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment (PHASE1)
- SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors (NA)
- A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab Injection CI brief — competitive landscape report
- Tislelizumab Injection updates RSS · CI watch RSS
- Nanjing Leads Biolabs Co.,Ltd portfolio CI